JP2023514732A5 - - Google Patents
Info
- Publication number
- JP2023514732A5 JP2023514732A5 JP2022550240A JP2022550240A JP2023514732A5 JP 2023514732 A5 JP2023514732 A5 JP 2023514732A5 JP 2022550240 A JP2022550240 A JP 2022550240A JP 2022550240 A JP2022550240 A JP 2022550240A JP 2023514732 A5 JP2023514732 A5 JP 2023514732A5
- Authority
- JP
- Japan
- Prior art keywords
- improvement
- pharmaceutical composition
- reduction
- individual
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062979214P | 2020-02-20 | 2020-02-20 | |
| US62/979,214 | 2020-02-20 | ||
| PCT/US2021/018906 WO2021168349A1 (en) | 2020-02-20 | 2021-02-19 | Pharmaceutical compositions of alpha-2-adrenergic receptor agonists and their use for improving vision |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023514732A JP2023514732A (ja) | 2023-04-07 |
| JP2023514732A5 true JP2023514732A5 (enExample) | 2024-02-28 |
Family
ID=74875311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550240A Pending JP2023514732A (ja) | 2020-02-20 | 2021-02-19 | アルファ－２－アドレナリン受容体アゴニストの医薬組成物および視力を改善するためのその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210260041A1 (enExample) |
| EP (1) | EP4106728A1 (enExample) |
| JP (1) | JP2023514732A (enExample) |
| KR (1) | KR20220157392A (enExample) |
| CN (1) | CN115443125A (enExample) |
| AU (1) | AU2021224232A1 (enExample) |
| BR (1) | BR112022016730A2 (enExample) |
| CA (1) | CA3168767A1 (enExample) |
| IL (1) | IL295782A (enExample) |
| MX (1) | MX2022010317A (enExample) |
| TW (1) | TW202139998A (enExample) |
| WO (1) | WO2021168349A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022182740A1 (en) | 2021-02-24 | 2022-09-01 | Ocular Therapeutix, Inc. | Intracanalicular depot inserter device |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478858A (en) * | 1993-12-17 | 1995-12-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists |
| US6495583B1 (en) | 1997-03-25 | 2002-12-17 | Synaptic Pharmaceutical Corporation | Benzimidazole derivatives |
| KR102337046B1 (ko) | 2010-01-22 | 2021-12-08 | 알러간, 인코포레이티드 | 전방내 서방성 치료제 이식물 |
| WO2014159576A1 (en) * | 2013-03-14 | 2014-10-02 | Allergan, Inc. | Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes |
| ES2751681T3 (es) | 2013-03-15 | 2020-04-01 | Allergan Inc | Implante intraocular que contiene prostamida |
| EP2978406A1 (en) | 2013-03-27 | 2016-02-03 | Forsight Vision5, Inc. | Bimatoprost ocular silicone inserts and methods of use thereof |
| WO2014165308A2 (en) | 2013-04-01 | 2014-10-09 | Allergan, Inc. | Microsphere drug delivery system for sustained intraocular release |
| EP3283004A4 (en) | 2015-04-13 | 2018-12-05 | Forsight Vision5, Inc. | Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent |
| EP3840750A1 (en) * | 2018-08-21 | 2021-06-30 | Allergan, Inc. | The use of alpha-2-adrenergic receptor agonists for improving vision |
-
2021
- 2021-02-19 JP JP2022550240A patent/JP2023514732A/ja active Pending
- 2021-02-19 EP EP21712314.0A patent/EP4106728A1/en not_active Withdrawn
- 2021-02-19 TW TW110105859A patent/TW202139998A/zh unknown
- 2021-02-19 MX MX2022010317A patent/MX2022010317A/es unknown
- 2021-02-19 US US17/180,532 patent/US20210260041A1/en not_active Abandoned
- 2021-02-19 KR KR1020227032439A patent/KR20220157392A/ko not_active Withdrawn
- 2021-02-19 CA CA3168767A patent/CA3168767A1/en active Pending
- 2021-02-19 CN CN202180027733.2A patent/CN115443125A/zh active Pending
- 2021-02-19 AU AU2021224232A patent/AU2021224232A1/en not_active Abandoned
- 2021-02-19 WO PCT/US2021/018906 patent/WO2021168349A1/en not_active Ceased
- 2021-02-19 IL IL295782A patent/IL295782A/en unknown
- 2021-02-19 BR BR112022016730A patent/BR112022016730A2/pt not_active Application Discontinuation
-
2024
- 2024-02-12 US US18/439,468 patent/US20240335425A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6273092B1 (en) | Methods for treating various eye disorders | |
| US11278545B2 (en) | Optical correction | |
| JP2023103400A (ja) | 老視を治療するための組成物及び方法 | |
| CN107847492A (zh) | 用于改善远视力和治疗眼睛屈光不正的组合物 | |
| CN108883102A (zh) | 用于治疗远视眼的组合物和方法 | |
| JP7174175B2 (ja) | 近視の治療、近視の予防および／または近視の進行抑制のための医薬 | |
| TW202333700A (zh) | 用於治療眼病之組成物及方法 | |
| RU2136252C1 (ru) | Противовоспалительные глазные капли | |
| JP6771698B1 (ja) | ウルソデオキシコール酸を含有する老視の治療または予防剤 | |
| CN118922190A (zh) | 用于治疗眼病的组合物及方法 | |
| WO2020129965A1 (ja) | ４－フェニル酪酸を含有する老視の治療または予防剤 | |
| CA2398158A1 (en) | Ophthalmic use of alpha adrenergic blocking agents | |
| JP2021534217A5 (enExample) | ||
| JPS61233622A (ja) | 眼薬組成物 | |
| US5200180A (en) | Pharmaceutical composition for the treatment of the human eye | |
| JP2024524433A (ja) | 白内障および老眼眼疾患を予防および治療するための薬理学的薬剤 | |
| RU2229864C1 (ru) | Способ лечения инфекционных язв и кератитов | |
| EP4342472A1 (en) | Eye drop for suppressing myopia | |
| TW202317132A (zh) | 眼用組合物及/或用於老花眼、瞳孔放大及/或眼部不適管理之方法 | |
| JP2020514347A (ja) | チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤 | |
| JPS63502270A (ja) | 散瞳作用を有する眼科用医薬組成物 | |
| US20260083730A1 (en) | Methods of treating eye disorders | |
| HK40118313A (en) | α1 BLOCKER-CONTAINING EYEDROPS FOR INHIBITING MYOPIA PROGRESSION | |
| WO2003086465A1 (fr) | Medicament pour la chirurgie correctrice de la myopie | |
| JP2025065516A (ja) | α１ブロッカーを含む近視進行抑制用点眼剤 |